Clinical Trials Logo

Stable Coronary Disease clinical trials

View clinical trials related to Stable Coronary Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05152888 Recruiting - Clinical trials for Stable Coronary Disease

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

EMPOWER
Start date: March 3, 2022
Phase: Phase 4
Study type: Interventional

The study protocol is a single-arm, open label pilot study designed to evaluate the impact of PCSK-9 inhibition on coronary blood flow in patients with stable coronary artery disease. Patients with stable coronary artery disease will be recruited from the BWH Cardiovascular Medicine clinic and/or from the BWH Nuclear Cardiology Laboratory. A target sample size of 50 participants will undergo imaging with N-13 ammonia or Rubidium-82 positron emission tomography (PET) and coronary computed tomography angiography (CCTA) before and after 12 months of PCSK-9 inhibition with Evolocumab to assess changes in myocardial blood flow, and plaque volume. To help account for physiological changes that may occur in myocardial blood flow and inflammatory biomarkers during the study period, we will also recruit a parallel control group of stable CAD patients who will undergo similar baseline and 12-month imaging and biomarker assessment. We plan to recruit 15 patients in the parallel control group.

NCT ID: NCT02797158 Completed - Clinical trials for Stable Coronary Disease

Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study

REVASC-TAVI
Start date: June 23, 2016
Phase: N/A
Study type: Interventional

Evaluation of a strategy of selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.

NCT ID: NCT02214654 Not yet recruiting - Clinical trials for Stable Coronary Disease

A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage

Start date: August 2014
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to compare clopidogrel with ticagrelor which one has stronger anti-inflammation effect to protect against type 2 diabetes-induced vascular damage.

NCT ID: NCT01122719 Terminated - Clinical trials for Stable Coronary Disease

Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen

BEST
Start date: October 2010
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of the Janus OPTIMA Tacrolimus-Eluting Stent (Optima TES, CID) for the treatment of de novo coronary lesions when associated with short-term (two months) dual antiplatelet (aspirin + clopidogrel) regimen.